⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 19, 2024MedicineOpen Access

Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer

Mingyu Meng Xiaoxia Liu Xueyan Liang Xiaoyu Chen Yan Li

View Full Paper

Ask AI

Bookmark

Share

Abstract

Durvalumab plus etoposide-platinum (DEP) showed sustained overall survival improvements in patients with extensive-stage small-cell lung cancer (ES-SCLC) compared to etoposide-platinum (EP), but adding tremelimumab to DEP (DTEP) did not significantly improve outcomes. A third-party payer perspective is taken here to evaluate the cost-effectiveness of DTEP, DEP, and EP for ES-SCLC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meng et al. (2024) studied this question.

synapsesocial.com/papers/68e6e65fb6db643587661874 https://doi.org/10.1097/md.0000000000037836

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Tremelimumab and durvalumab with chemotherapy in first-line treatment for metastatic non-small cell lung cancer: a US-based cost-effectiveness analysis2024 · 1 citations
2Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer – a grade-assessed network meta-analysis of randomized controlled trialsMeta-Analysis · 2026 · 1 citations
3Survival outcomes with first-line platinum–etoposide plus durvalumab versus platinum–etoposide alone in extensive-stage small cell lung cancer with metastatic disease including brain metastases: A real world analysis.Cohort Study · 2026
4Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study).2024 · 5 citations
5Toripalimab plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer: a health economic evaluation in China2025 · 1 citations

More related papers

Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study2025
Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer2025
Paclitaxel, carboplatin, and durvalumab in extensive stage small-cell lung cancer (ES-SCLC; IFCT-2203 TAXIO phase II trial): Can we improve the chemotherapy (CT) immunotherapy combination in SCLC?2026

More from Medicine

Association of one-stop administrative and logistics services with patient satisfaction in smart hospitalsFri,
Burden of CNS neoplasms in the Middle East and North Africa from 1990 to 2023, with projections to 2050Fri,